July 28, 2015 / 11:30 AM / 3 years ago

Merck raises forecast on strong sales of diabetes, cancer drugs

(Reuters) - Merck & Co Inc (MRK.N) reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased.

The company also said it expects to reap benefits from its $8.4 billion purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin. Cubicin sales for the second quarter were $293 million.

Sales of Merck’s diabetes drug, Januvia, rose 1.3 percent to $1.6 billion in the quarter ended June 30.

The company’s cancer treatment from a promising class of new drugs, Keytruda, brought in sales of $110 million, helping the drugmaker edge past the average analyst estimate for revenue.

The 124-year-old company raised its forecast to $3.45-$3.55 per share from $3.35-$3.48 per share. Analysts on average were expecting $3.45 per share, according to Thomson Reuters I/B/E/S.

In the second quarter, Merck’s net income fell nearly 66 percent to $687 million, or 24 cents per share, for the second quarter, from $2 billion, or 68 cents per share, from a year earlier.

The latest reported quarter included charges of $1.45 billion related to the Cubist deal.

Excluding items, the company earned 86 cents per share. Revenue fell 10.5 percent to $9.79 billion.

    Analysts on average had expected a profit of 81 cents per share on revenue of $9.8 billion, according to Thomson Reuters I/B/E/S.

    Separately, the company said it would buy privately held drug developer cCAM Biotherapeutics for $95 million to boost its immuno-oncology pipeline.

    The deal also includes milestone payments of $510 million.

    Merck’s shares were up marginally at $57.50 on Tuesday in premarket trading. They had fallen about 1 percent this year through Monday’s close, compared with a 9 percent rise in the S&P 500 healthcare index .SPXHC.

    Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below